checkAd
SRH AlsterResearch AG Update: Symrise AG - Solid take-off in 2021, but fairly valued; HOLD

SRH AlsterResearch AG Update: Symrise AG - Solid take-off in 2021, but fairly valued; HOLD

Nachrichtenquelle: AlsterResearch AG
30.04.2021, 10:49  |  113   |   |   

Symrise had a strong start to 2021, with organic sales increasing a 10.5% yoy in Q1 2021, owing to deferred benefits from the delivery backlog that resulted from the cyberattack in December 2020.

Symrise AG (Update)

Chemicals
MCap EUR 14.7bn

HOLD, PT EUR 100.00 (-8% potential)
Research_update

Symrise had a strong start to 2021, with organic sales increasing a 10.5% yoy in Q1 2021, owing to deferred benefits from the delivery backlog that resulted from the cyberattack in December 2020. Management confirmed its 2021 and mid-term targets, which seem achievable on an expanded portfolio and planned integration of the Flavor and Nutrition divisions, which may offer strong cross-selling opportunities. Despite the high quality of the business model, the current valuation levels seem to be fair in our point of view. Hence, we reiterate our HOLD recommendation as well as our DCF-based price target of EUR 100.00.

 

For 5 current investment ideas, check our Weekly Screener. This week we are looking for companies that have the highest Return on Capital Employed (ROCE)

Please note that AlsterResearch publishes MiFID II compliant research only. For a detailed discussion on MiFID II, please visit https://www.research-hub.de

Symrise Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de

Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

SRH AlsterResearch AG Update: Symrise AG - Solid take-off in 2021, but fairly valued; HOLD Symrise had a strong start to 2021, with organic sales increasing a 10.5% yoy in Q1 2021, owing to deferred benefits from the delivery backlog that resulted from the cyberattack in December 2020. Management confirmed its 2021 and mid-term targets, which seem achievable on an expanded portfolio and planned integration of the Flavor and Nutrition divisions, which may offer strong cross-selling opportunities.

Community

Nachrichten des Autors

Titel
Titel
Titel